Advertisement
News
Subscribe to MDT Magazine News

PharmaGap Announces Conversion of Amounts Owed to Founding Directors Into Common Shares

May 10, 2011 12:45 pm | by The Associated Press | Comments

PharmaGap Inc. (TSX VENTURE: GAP) (OTCBB: PHRGF) ("PharmaGap" or "the Company") today announced that it has reached agreement with Dr. Jenny Phipps, Mr. Robert Letellier, and Mr. Daniel Larkin, (the "Subscribers") each of whom is a director and founder of the Company, to convert an...

Quest agrees to $241M Calif. Medicaid settlement

May 10, 2011 12:45 pm | by The Associated Press | Comments

Medical laboratory operator Quest Diagnostics Inc. has agreed to pay $241 million to resolve a civil lawsuit over California Medicaid payments.The Madison, N.J., company said late Monday that it is settling a lawsuit that alleged that Quest didn't comply with California regulations, leading the...

Cobalis Corp. Launches National Television Commercials for PreHistin® Allergy Defense Formula

May 10, 2011 12:35 pm | by Bio-Medicine.Org | Comments

IRVINE, Calif., May 10, 2011 /- Cobalis Corp. (CLSC.PK) announced today they have started airing 60-second television commercials for PreHistin® Allergy Defense Formula , on major national cable and satellite networks across the US. The commercials, featuring leading US allergist Dr....

TOPICS:
Advertisement

Consumer Information on: Scandinavian Total Ankle Replacement System (STAR Ankle) - P050050

May 10, 2011 11:41 am | by U.S. Food & Drug Administration | Comments

The STAR Ankle is a non-constrained, total ankle replacement, surgically implanted to replace an ankle joint. The STAR Ankle is non-constrained because the bearing can be free to move in more than one plane along the tibial component.

Adeona to Host First Quarter 2011 Investor Conference Call

May 10, 2011 11:36 am | by Bio-Medicine.Org | Comments

ANN ARBOR, Mich., May 10, 2011 /- Adeona Pharmaceuticals, Inc. (AMEX: AEN ), a developer of innovative medicines for serious central nervous system diseases, announced today that it will hold its 1st quarter 2011 investor conference call on Tuesday, May 17, 2011, at 1:00pm EDT. James S....

TOPICS:

Pierrel Research USA Launches Orablocâ„¢ a New Purer Articaine

May 10, 2011 11:36 am | by Bio-Medicine.Org | Comments

WAYNE, Pa., May 10, 2011 /- Pierrel Research USA, Inc. ( www.pierrel-research-usa.com ), a subsidiary of Pierrel SpA, the Italian-based, global pharmaceutical services company ( www.pierrel.it ), announces the US launch of Orabloc™ (Articaine hydrochloride 4% with epinephrine...

TOPICS:

American Imaging Management Named as Finalist for 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection

May 10, 2011 10:32 am | by Bio-Medicine.Org | Comments

CHICAGO, May 10, 2011 /- American Imaging Management (AIM) was selected as one of 20 finalists for the 2011 URAC Awards for Best Practices in Health Care Consumer Empowerment and Protection. URAC, the nation's leading accreditation organization, will honor the finalists during URAC's 12th...

TOPICS:

Mindray shares jump on 1Q profit boost

May 10, 2011 9:45 am | by The Associated Press | Comments

Shares of medical device maker Mindray Medical International Ltd. jumped Tuesday after the company reported a 4 percent boost in first-quarter profit and reaffirmed its growth outlook.The stock rose $2.73, or 9.9 percent, to $30.27 in afternoon trading. Shares have traded between $25 and $35.95...

Advertisement

RNA spurs melanoma development

May 10, 2011 9:37 am | by EurekAlert | Comments

(Sanford-Burnham Medical Research Institute) Researchers at Sanford-Burnham Medical Research Institute and the University of Queensland show that long, non-coding RNA (lncRNA) levels are altered in human melanoma. Their study, published online May 10 by the journal Cancer Research,...

TOPICS:

Surgical Care Affiliates Announces Investor Conference Call to Discuss 2011 First Quarter Results

May 10, 2011 9:35 am | by Bio-Medicine.Org | Comments

BIRMINGHAM, Ala., May 10, 2011 /- Surgical Care Affiliates ("SCA") today announced that it will host an investor conference call at 10:00 a.m. Central Time on Monday, May 16, 2011, to discuss its 2011 first quarter operating results. A 30-day replay will be available approximately an hour...

TOPICS:

NMT Medical, Inc. Sealed Bid Sale of its Intellectual Property to Take Place Friday, June 10, 2011 at Twelve O'Clock Noon

May 10, 2011 9:34 am | by Bio-Medicine.Org | Comments

WELLESLEY HILLS, Mass., May 10, 2011 /- On Friday, June 10, 2011 at twelve o'clock noon, NMT Medical, Inc. intellectual property, which has been assigned to Joseph F. Finn, Jr., C.P.A. ("Finn") of the firm Finn, Warnke & Gayton, LLP will be liquidated for the benefit of NMT Medical...

TOPICS:

83 Cases of Autism Associated with Childhood Vaccine Injury Compensated in Federal Vaccine Court

May 10, 2011 9:33 am | by Bio-Medicine.Org | Comments

WASHINGTON, May 10, 2011 /PRNewswire-USNewswire/ -- The following is being released by SafeMinds ( www.SafeMinds.org ): For over 20 years, the federal government has publicly denied a vaccine-autism link, while at the same time its Vaccine Injury Compensation Program (VICP) has been...

TOPICS:

Boston Scientific CEO will retire at year-end

May 10, 2011 8:45 am | by MARLEY SEAMAN - AP Health Writers - Associated Press | Comments

Medical device maker Boston Scientific Corp. announced Tuesday that its Chief Executive Ray Elliott will retire as president and CEO at the end of the year, after just over two years leading the company.Elliott's departure was unexpected and sent company shares tumbling more than 10 percent.The...

Myriad signs licensing deal for cancer tests

May 10, 2011 7:45 am | by The Associated Press | Comments

Molecular diagnostics company Myriad Genetics Inc. said Tuesday that it signed a deal to license technology for the early detection of cancer from Chronix Biomedical.Terms of the deal were not disclosed.Myriad, based in Salt Lake City, said it receives rights to sell tests for the early...

Micromet 1Q loss narrows on warrant gain

May 10, 2011 7:45 am | by The Associated Press | Comments

Cancer drug developer Micromet Inc. said Tuesday its first-quarter loss narrowed on a boost from the value of warrants.The company reported a net loss of $8.2 million, or 9 cents per share, in the three months that ended March 31. That compares with a net loss of $18.3 million, or 26 cents per...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading